Hybrid FC (hyFC) fusion proteins, Genexine

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameHybrid FC (hyFC) fusion proteins, Genexine
Drug Alias Namehybrid Fc fusion protein therapy (blood clotting disorder)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionUpdating
TargetsNot applicable
Therapy Area/IndicationsAnemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGannex Pharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGannex Pharma Co Ltd
Active IndicationsN/A
Inactive IndicationsAnemia

Other Information

ATC CodeN/A
Related LinksN/A